Cerebral embolic protection devices (EPDs) were developed to mitigate the risk of stroke during transcatheter aortic valve replacement (TAVR), but their benefit remains unproven. In the PROTECTED-TAVR trial, EPD use did not reduce periprocedural stroke (primary study outcome) but led to a 62% reduction in the secondary endpoint of disabling stroke. Given these results, the impact of EPDs during TAVR remains unclear.
Each week, we present a journal club in which we choose a study that we believe will be of interest to the interventional cardiology community and discuss it at a virtual journal club with several of our faculty members.
Panelists
Presenter
